Literature DB >> 29444915

Predictors of accelerated decline in lung function in adult-onset asthma.

Hanneke Coumou1, Guus A Westerhof2, Selma B de Nijs2, Aeilko H Zwinderman3, Elisabeth H Bel2.   

Abstract

Little is known about the prognosis of adults with new-onset asthma. Cross-sectional studies suggest that these patients may exhibit accelerated decline in forced expiratory volume in 1 s (FEV1). However, risk factors for accelerated decline in lung function have not yet been identified.We aimed to identify these risk factors in a prospective 5-year follow-up study in 200 adults with newly diagnosed asthma. In the current study, clinical, functional and inflammatory parameters were assessed annually for 5 years. Linear mixed-effects models were used to identify predictors.Evaluable lung function sets of 141 patients were available. Median (interquartile range) change in post-bronchodilator FEV1 was -17.5 (-54.2 to +22.4) mL per year. Accelerated decline in FEV1 was defined by the lower quartile of decline (>54.2 mL per year). Nasal polyps, number of blood and sputum eosinophils, body mass index, and level of exhaled nitric oxide were univariably associated with decline in lung function. Only the latter two were independently associated. Using cut-off values to identify patients at highest risk showed accelerated decline in FEV1 in all patients with combined exhaled nitric oxide fraction (FeNO) ≥57 ppb and body mass index (BMI) ≤23 kg·m-2We conclude that adults with new-onset asthma with both high levels of exhaled nitric oxide and low BMI are at risk of accelerated decline in lung function.
Copyright ©ERS 2018.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29444915     DOI: 10.1183/13993003.01785-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  15 in total

1.  Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors.

Authors:  Yuki Maruyama; Takuya Sadahira; Yosuke Mitsui; Motoo Araki; Koichiro Wada; Ryuta Tanimoto; Yasuyuki Kobayashi; Masami Watanabe; Toyohiko Watanabe; Yasutomo Nasu
Journal:  Med Oncol       Date:  2018-04-26       Impact factor: 3.064

2.  Responsiveness to Parenteral Corticosteroids and Lung Function Trajectory in Adults with Moderate-to-Severe Asthma.

Authors:  Loren C Denlinger; Brenda R Phillips; Ronald L Sorkness; Eugene R Bleecker; Mario Castro; Mark D DeBoer; Anne M Fitzpatrick; Annette T Hastie; Jonathan M Gaffin; Wendy C Moore; Michael C Peters; Stephen P Peters; Wanda Phipatanakul; Juan Carlos Cardet; Serpil C Erzurum; John V Fahy; Merritt L Fajt; Benjamin Gaston; Bruce D Levy; Deborah A Meyers; Kristie Ross; W Gerald Teague; Sally E Wenzel; Prescott G Woodruff; Joe Zein; Nizar N Jarjour; David T Mauger; Elliot Israel
Journal:  Am J Respir Crit Care Med       Date:  2021-04-01       Impact factor: 21.405

3.  Quantitative CT metrics are associated with longitudinal lung function decline and future asthma exacerbations: Results from SARP-3.

Authors:  James G Krings; Charles W Goss; Daphne Lew; Maanasi Samant; Mary Clare McGregor; Jonathan Boomer; Leonard B Bacharier; Ajay Sheshadri; Chase Hall; Joshua Brownell; Ken B Schechtman; Samuel Peterson; Stephen McEleney; David T Mauger; John V Fahy; Sean B Fain; Loren C Denlinger; Elliot Israel; George Washko; Eric Hoffman; Sally E Wenzel; Mario Castro
Journal:  J Allergy Clin Immunol       Date:  2021-02-09       Impact factor: 14.290

Review 4.  Addressing the risk domain in the long-term management of pediatric asthma.

Authors:  Eckard Hamelmann; Erika von Mutius; Andrew Bush; Stanley J Szefler
Journal:  Pediatr Allergy Immunol       Date:  2019-12-11       Impact factor: 6.377

Review 5.  The Role of FeNO in Predicting Asthma.

Authors:  Mariëlle W Pijnenburg
Journal:  Front Pediatr       Date:  2019-02-21       Impact factor: 3.418

Review 6.  Asthma progression and mortality: the role of inhaled corticosteroids.

Authors:  Paul O'Byrne; Leonardo M Fabbri; Ian D Pavord; Alberto Papi; Stefano Petruzzelli; Peter Lange
Journal:  Eur Respir J       Date:  2019-07-18       Impact factor: 16.671

Review 7.  Defining severe obstructive lung disease in the biologic era: an endotype-based approach.

Authors:  Richard J Martin; Elisabeth H Bel; Ian D Pavord; David Price; Helen K Reddel
Journal:  Eur Respir J       Date:  2019-11-21       Impact factor: 16.671

8.  Bronchodilator response and lung function decline: Associations with exhaled nitric oxide with regard to sex and smoking status.

Authors:  Elisabet Nerpin; Diogenes Seraphim Ferreira; Joost Weyler; Vivi Schlunnsen; Rain Jogi; Chantal Raherison Semjen; Thorainn Gislasson; Pascal Demoly; Joachim Heinrich; Dennis Nowak; Angelo Corsico; Simone Accordini; Alessandro Marcon; Giulia Squillacioti; Mario Olivieri; Rune Nielsen; Ane Johannessen; Francisco Gómez Real; Judith Garcia-Aymerich; Isabel Urrutia; Antonio Pereira-Vega; Jose Antonio Gullón; Anna-Carin Olin; Bertil Forsberg; Össur Ingi Emilsson; Isabelle Pin; Deborah Jarvis; Christer Janson; Andrei Malinovschi
Journal:  World Allergy Organ J       Date:  2021-05-18       Impact factor: 4.084

9.  12-year adherence to inhaled corticosteroids in adult-onset asthma.

Authors:  Iida Vähätalo; Pinja Ilmarinen; Leena E Tuomisto; Minna Tommola; Onni Niemelä; Lauri Lehtimäki; Pentti Nieminen; Hannu Kankaanranta
Journal:  ERJ Open Res       Date:  2020-03-23

10.  FEV1 decline in relation to blood eosinophils and neutrophils in a population-based asthma cohort.

Authors:  Helena Backman; Anne Lindberg; Linnea Hedman; Caroline Stridsman; Sven-Arne Jansson; Thomas Sandström; Bo Lundbäck; Eva Rönmark
Journal:  World Allergy Organ J       Date:  2020-03-17       Impact factor: 4.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.